AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35098682 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomogram combining radiomics and clinical features
Number of subjects: 1092
Study 32737604 — intervention group
Group type: EXPERIMENTAL
Intervention: Dose-Response Mixed Models for Repeated Measures (DR-MMRM)
Number of subjects: 0
Study 32737604 — intervention group
Group type: COMPARATOR
Intervention: Conventional Mixed Models for Repeated Measures (MMRM)
Number of subjects: 0
Study 32737604 — intervention group
Group type: COMPARATOR
Intervention: Dose-response model
Number of subjects: 0
Study 33880653 — intervention group
Group type: EXPERIMENTAL
Intervention: Reversed total shoulder prosthetic replacement (RTSA)
Number of subjects: 54
Study 33880653 — intervention group
Group type: COMPARATOR
Intervention: Open reduction and internal fixation (ORIF) using a proximal humerus locking plate (PHILOS)
Number of subjects: 54
Study 33076902 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen treatment
Number of subjects: 76
Study 33076902 — intervention group
Group type: COMPARATOR
Intervention: Untreated control
Number of subjects: 76
Study 36061219 — intervention group
Group type: EXPERIMENTAL
Intervention: Food Choice Questionnaire (FCQ)
Number of subjects: 385
Study 32195215 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior change group (n = 36)
Number of subjects: 114
Study 32195215 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional exercise group (n = 52)
Number of subjects: 114
Study 32195215 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 26)
Number of subjects: 114
Study 33837086 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketogenic diet (KD)
Number of subjects: 33
Study 33837086 — intervention group
Group type: COMPARATOR
Intervention: Standard American (SA) diet
Number of subjects: 33
Study 35021015 — intervention group
Group type: EXPERIMENTAL
Intervention: Linguistic-phonological intervention to eliminate anterior oral CSCs
Number of subjects: 14
Study 35021015 — intervention group
Group type: COMPARATOR
Intervention: Motor-phonetic intervention to eliminate anterior oral CSCs
Number of subjects: 14
Study 35021015 — intervention group
Group type: EXPERIMENTAL
Intervention: Motor-phonetic intervention to eliminate non-oral CSCs
Number of subjects: 14
Study 35021015 — intervention group
Group type: COMPARATOR
Intervention: Linguistic-phonological intervention to eliminate non-oral CSCs
Number of subjects: 14
Study 33648474 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapeutic exercise program (12 weeks, face-to-face, with home-based program 3 sessions per week)
Number of subjects: 48
Study 33648474 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal-directed therapeutic exercise program
Number of subjects: 48
Study 33648474 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 48
Study 36294321 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-emitting eyeglass frames (VLf) that emitted VL of 310 μW/cm2 (n = 22)
Number of subjects: 43
Study 36294321 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-placebo eyeglass frames with a minimal emission of VL (<10 μW/cm2) (control group, n = 21)
Number of subjects: 43
Study 36294321 — intervention group
Group type: EXPERIMENTAL
Intervention: VL-emitting eyeglass frames (VLf)
Number of subjects: 43
Study 36294321 — intervention group
Group type: COMPARATOR
Intervention: Pseudo-placebo eyeglass frames (control group)
Number of subjects: 43
Study 34678709 — intervention group
Group type: EXPERIMENTAL
Intervention: Nine-session anxiety prevention program
Number of subjects: 86
Study 34678709 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control condition
Number of subjects: 86
Study 33609135 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 24 hours (TTM24)
Number of subjects: 311
Study 33609135 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management at 33°C for 48 hours (TTM48)
Number of subjects: 311
Study 33609135 — intervention group
Group type: EXPERIMENTAL
Intervention: From 24 to 48 hours in TTM48 group
Number of subjects: 311
Study 33609135 — intervention group
Group type: EXPERIMENTAL
Intervention: High vasopressor load
Number of subjects: 311
Study 34184976 — intervention group
Group type: EXPERIMENTAL
Intervention: Concussion Coach
Number of subjects: 461
Study 34184976 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-Usual (TAU)
Number of subjects: 461
Study 32757569 — intervention group
Group type: EXPERIMENTAL
Intervention: Training condition where children were taught about sarcasm and cues to look for during interactions with the researcher.
Number of subjects: 111
Study 32757569 — intervention group
Group type: COMPARATOR
Intervention: Control condition where children read a nonsarcastic storybook with the researcher.
Number of subjects: 111
Study 32381840 — intervention group
Group type: EXPERIMENTAL
Intervention: SRP plus Periochip™
Number of subjects: 20
Study 32381840 — intervention group
Group type: COMPARATOR
Intervention: SRP alone
Number of subjects: 20
Study 36368761 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate mobilisation
Number of subjects: 240
Study 36368761 — intervention group
Group type: COMPARATOR
Intervention: Postoperative 2-week casting
Number of subjects: 240
Study 33125272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic floor muscle plus abdominal training (PFMT+AT)
Number of subjects: 64
Study 33125272 — intervention group
Group type: COMPARATOR
Intervention: Pelvic floor muscle training (PFMT)
Number of subjects: 64
Study 32517192 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral magnesium supplementation (400 mg magnesium/day in the form of magnesium oxide)
Number of subjects: 52
Study 32517192 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study 35001651 — intervention group
Group type: EXPERIMENTAL
Intervention: carboxytherapy and vibratory device A
Number of subjects: 78
Study 35001651 — intervention group
Group type: EXPERIMENTAL
Intervention: carboxytherapy and vibratory device B
Number of subjects: 78
Study 35001651 — intervention group
Group type: COMPARATOR
Intervention: control group
Number of subjects: 78
Study 33184437 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary probiotic supplement of four viable strains of Lactobacillus twice-daily for 14 days
Number of subjects: 82
Study 33184437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 35063952 — intervention group
Group type: EXPERIMENTAL
Intervention: MetaWell programme (diet replacement products, wireless scales, mobile phone app)
Number of subjects: 220
Study 35063952 — intervention group
Group type: COMPARATOR
Intervention: Paper material containing a sample diet for weight loss
Number of subjects: 220
Study 33037656 — intervention group
Group type: EXPERIMENTAL
Intervention: recombinant human GH (rhGH)
Number of subjects: 24
Study 33037656 — intervention group
Group type: COMPARATOR
Intervention: no treatment
Number of subjects: 24
Study 35407595 — intervention group
Group type: EXPERIMENTAL
Intervention: Negative pulsed-pressure myofascial vacuum therapy (VT)
Number of subjects: 50
Study 35407595 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy program (PTP) based only on core therapeutic exercise
Number of subjects: 50
Study 32763548 — intervention group
Group type: EXPERIMENTAL
Intervention: Sertraline (50 mg)
Number of subjects: 45
Study 32763548 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine (100 mg)
Number of subjects: 45
Study 32763548 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (10 mg)
Number of subjects: 45
Study 34150674 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral liposomal glutathione supplementation (L-GSH) for 3 months
Number of subjects: 0
Study 32433194 — intervention group
Group type: EXPERIMENTAL
Intervention: C-arm
Number of subjects: 12
Study 32433194 — intervention group
Group type: COMPARATOR
Intervention: O-arm
Number of subjects: 12
Study 36325677 — intervention group
Group type: EXPERIMENTAL
Intervention: Electroacupuncture (EA) once a week for 12 weeks
Number of subjects: 60
Study 36325677 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture (SA)
Number of subjects: 60
Study 34446114 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouldering psychotherapy (BPT)
Number of subjects: 233
Study 34446114 — intervention group
Group type: COMPARATOR
Intervention: Cognitive behavioral therapy (CBT)
Number of subjects: 233
Study 34446114 — intervention group
Group type: COMPARATOR
Intervention: Home-based physical exercise program (EP)
Number of subjects: 233
Study 33211710 — intervention group
Group type: EXPERIMENTAL
Intervention: Integration of TB screening into IMNCI clinics during intervention period
Number of subjects: 180896
Study 33211710 — intervention group
Group type: EXPERIMENTAL
Intervention: Contact investigation in TB clinics during intervention period
Number of subjects: 180896
Study 33211710 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall integration of TB screening and contact investigation
Number of subjects: 180896
Study 35833298 — intervention group
Group type: EXPERIMENTAL
Intervention: 7+3 induction chemotherapy
Number of subjects: 1247
Study 34526067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab
Number of subjects: 438
Study 34526067 — intervention group
Group type: EXPERIMENTAL
Intervention: Eculizumab
Number of subjects: 438
Study 34526067 — intervention group
Group type: EXPERIMENTAL
Intervention: Ravulizumab and Eculizumab
Number of subjects: 438
Study 34228086 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic initiation letter (n = 1500)
Number of subjects: 3465
Study 34228086 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic duration letter (n = 1500)
Number of subjects: 3465
Study 34228086 — intervention group
Group type: COMPARATOR
Intervention: Control group (no letter; n = 500)
Number of subjects: 3465
Study 32033576 — intervention group
Group type: EXPERIMENTAL
Intervention: Checklist-based box system interventions
Number of subjects: 1200
Study 32033576 — intervention group
Group type: COMPARATOR
Intervention: Routine standard of care
Number of subjects: 1200
Study 35820743 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg guanabenz acetate
Number of subjects: 28
Study 35820743 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg guanabenz acetate
Number of subjects: 28
Study 32755065 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct perineal wound full-thick closure (DPWC)
Number of subjects: 44
Study 32755065 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy (NPA group)
Number of subjects: 44
Study 32755065 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypoalbuminemia
Number of subjects: 44
Study 32755065 — intervention group
Group type: COMPARATOR
Intervention: Conventional perineal wound closure (CPWC)
Number of subjects: 44
Study 35325597 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D supplementation
Number of subjects: 0
Study 35325597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 35762390 — intervention group
Group type: EXPERIMENTAL
Intervention: IDegLira
Number of subjects: 720
Study 35762390 — intervention group
Group type: COMPARATOR
Intervention: Degludec
Number of subjects: 720
Study 35762390 — intervention group
Group type: COMPARATOR
Intervention: Liraglutide
Number of subjects: 720
Study 33413417 — intervention group
Group type: EXPERIMENTAL
Intervention: Seasonal Malaria Chemoprevention (SMC) for 4 years
Number of subjects: 461
Study 33413417 — intervention group
Group type: COMPARATOR
Intervention: Seasonal Malaria Chemoprevention (SMC) for 2 years
Number of subjects: 461
Study 32375688 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 cycles of neoadjuvant chemotherapy (NAC)
Number of subjects: 298
Study 32375688 — intervention group
Group type: COMPARATOR
Intervention: 3 cycles of neoadjuvant chemotherapy (NAC)
Number of subjects: 298
Study 32375688 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups will undergo interval debulking surgery (IDS) and then receive 3 or 4 cycles of adjuvant chemotherapy for a total of 6 cycles.
Number of subjects: 298
Study 34448876 — intervention group
Group type: EXPERIMENTAL
Intervention: Full-length transcriptome SMRT and Illumina RNA sequencing
Number of subjects: 0
Study 34448876 — intervention group
Group type: EXPERIMENTAL
Intervention: Gas chromatography-mass spectrometry
Number of subjects: 0
Study 34885998 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive structured intervention to improve motor skills
Number of subjects: 471
Study 34885998 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 471
Study 32221043 — intervention group
Group type: EXPERIMENTAL
Intervention: Active tDCS
Number of subjects: 10
Study 32221043 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 10
Study 35569564 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers indicating cardiorenal dysfunction and inflammation (NT‐proBNP, troponin T, cystatin C, GDF‐15, IL‐6, CRP) in patients with HFrEF
Number of subjects: 11818
Study 35569564 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers indicating cardiorenal dysfunction and inflammation (NT‐proBNP, troponin T, cystatin C, GDF‐15, IL‐6, CRP) in patients with HFpEF
Number of subjects: 11818
Study 35569564 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomarkers indicating cardiorenal dysfunction and inflammation (NT‐proBNP, troponin T, cystatin C, GDF‐15, IL‐6, CRP) in patients with No HF
Number of subjects: 11818
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-satiety food (HSF) group
Number of subjects: 82
Study 33263788 — intervention group
Group type: COMPARATOR
Intervention: Lower-satiety food (LSF) group
Number of subjects: 82
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-energy diet (VLED)
Number of subjects: 82
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight maintenance (WM) period
Number of subjects: 82
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Fasting appetite-related hormones
Number of subjects: 82
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in ghrelin levels
Number of subjects: 82
Study 33263788 — intervention group
Group type: EXPERIMENTAL
Intervention: Changes in leptin and insulin levels
Number of subjects: 82
Study 34913497 — intervention group
Group type: EXPERIMENTAL
Intervention: TMFI + Steroid
Number of subjects: 21
Study 34913497 — intervention group
Group type: COMPARATOR
Intervention: Steroid injection
Number of subjects: 21
Study 33663090 — intervention group
Group type: EXPERIMENTAL
Intervention: Auricular acupoint stimulation
Number of subjects: 0
Study 33663090 — intervention group
Group type: COMPARATOR
Intervention: Sham acupressure
Number of subjects: 0
Study 32762115 — intervention group
Group type: EXPERIMENTAL
Intervention: Irbesartan 100 mg/amlodipine 10 mg (Group 1)
Number of subjects: 94
Study 32762115 — intervention group
Group type: EXPERIMENTAL
Intervention: Indapamide 1 mg in addition to ARBs plus amlodipine 5 mg (Group 2)
Number of subjects: 94
Study 36137765 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-transfusion haemoglobin <75g/L
Number of subjects: 0
Study 33350863 — intervention group
Group type: COMPARATOR
Intervention: Lebrikizumab (IL-13 inhibitor)
Number of subjects: 0
Study 33350863 — intervention group
Group type: COMPARATOR
Intervention: Tralokinumab (IL-13 monoclonal antibody)
Number of subjects: 0
Study 32822683 — intervention group
Group type: EXPERIMENTAL
Intervention: Back-and-forth technique
Number of subjects: 132
Study 32822683 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentric circle technique
Number of subjects: 132
Study 32822683 — intervention group
Group type: COMPARATOR
Intervention: Comparison of both techniques
Number of subjects: 132
Study 36124407 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior leaflet prolapse repair
Number of subjects: 74
Study 36124407 — intervention group
Group type: COMPARATOR
Intervention: Posterior leaflet prolapse repair
Number of subjects: 74
Study 36124407 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation
Number of subjects: 74
Study 36124407 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle end-systolic diameter
Number of subjects: 74
Study 36124407 — intervention group
Group type: EXPERIMENTAL
Intervention: Left ventricle end-systolic diameter ≤42 mm
Number of subjects: 74
Study 33516644 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Number of subjects: 24
Study 33516644 — intervention group
Group type: COMPARATOR
Intervention: Best Supportive Care (BSC)
Number of subjects: 24
Study 35325728 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebellar anodal transcranial direct current stimulation (a‐tDCS) concurrent with postural training (cerebellar a‐CSC‐PT)
Number of subjects: 37
Study 35325728 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCSC‐PT
Number of subjects: 37
Study 35325728 — intervention group
Group type: COMPARATOR
Intervention: Postural training alone
Number of subjects: 37
Study 32659768 — intervention group
Group type: EXPERIMENTAL
Intervention: Ostrich oil massage (1 mL on pruritus area for 10 min each night for 1 month)
Number of subjects: 68
Study 32659768 — intervention group
Group type: COMPARATOR
Intervention: Placebo massage
Number of subjects: 68
Study 36454825 — intervention group
Group type: EXPERIMENTAL
Intervention: eOD-GT8 60mer adjuvanted with AS01B
Number of subjects: 0
Study 36454825 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 34227708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 50 mg
Number of subjects: 324
Study 34227708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tegoprazan 100 mg
Number of subjects: 324
Study 34227708 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 324
Study 32217922 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative frailty and mobility assessments
Number of subjects: 0
Study 32217922 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly defined)
Number of subjects: 0
Study 32533763 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual lymphatic drainage (MLD)
Number of subjects: 49
Study 32533763 — intervention group
Group type: COMPARATOR
Intervention: Perineal massage
Number of subjects: 49
Study 36216204 — intervention group
Group type: COMPARATOR
Intervention: Midazolam (Group M)
Number of subjects: 40
Study 33446158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based text message intervention (45 text messages over 45 days)
Number of subjects: 136
Study 33446158 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone-based text message intervention
Number of subjects: 136
Study 33446158 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 136
Study 36399476 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based bilingual doula (CBD) support
Number of subjects: 164
Study 36399476 — intervention group
Group type: COMPARATOR
Intervention: Standard care (SC)
Number of subjects: 164
Study 35389054 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-adhesive low-level light therapy (LLLT) device (Color DNA-WSF) applied three times daily for 12 weeks
Number of subjects: 0
Study 35389054 — intervention group
Group type: COMPARATOR
Intervention: Sham device applied three times daily for 12 weeks
Number of subjects: 0
Study 35389054 — intervention group
Group type: EXPERIMENTAL
Intervention: Skin-adhesive low-level light therapy (LLLT) device (Color DNA-WSF)
Number of subjects: 0
Study 35389054 — intervention group
Group type: COMPARATOR
Intervention: Sham device
Number of subjects: 0
Study 35389054 — intervention group
Group type: EXPERIMENTAL
Intervention: Both LLLT and sham devices
Number of subjects: 0
Study 33704913 — intervention group
Group type: EXPERIMENTAL
Intervention: In-bed cycle exercise (20 minutes, 5 days per week for 3 weeks)
Number of subjects: 52
Study 33704913 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 52
Study 32768993 — intervention group
Group type: EXPERIMENTAL
Intervention: Insomnia Severity Index
Number of subjects: 123
Study 32768993 — intervention group
Group type: EXPERIMENTAL
Intervention: B-MAST
Number of subjects: 123
Study 33565051 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified needle (scrubbed with an 11 scalpel blade for 150 seconds)
Number of subjects: 16
Study 33565051 — intervention group
Group type: COMPARATOR
Intervention: Standard needle (control group A)
Number of subjects: 16
Study 32872022 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoablation combined with 28-days TCM formula
Number of subjects: 450
Study 32872022 — intervention group
Group type: COMPARATOR
Intervention: 4 cycles of chemotherapy
Number of subjects: 450
Study 36480678 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupressure
Number of subjects: 68
Study 36480678 — intervention group
Group type: COMPARATOR
Intervention: Acupressure Sham
Number of subjects: 68
Study 33219313 — intervention group
Group type: EXPERIMENTAL
Intervention: 125 mg MDMA
Number of subjects: 45
Study 33219313 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 32073564 — intervention group
Group type: EXPERIMENTAL
Intervention: Mometasone furoate nasal spray (MFNS)
Number of subjects: 50
Study 32073564 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal Glycyrrhetic acid (GlyAc)
Number of subjects: 50
Study 32073564 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 50
Study 34758065 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram or Duloxetine
Number of subjects: 121
Study 34758065 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 121
Study 34758065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant medication
Number of subjects: 121
Study 34758065 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant response
Number of subjects: 121
Study 611925637 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine supplementation (3 g/day for 7 days, then 6 g/day for 23 days)
Number of subjects: 14
Study 611925637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 611925637 — intervention group
Group type: EXPERIMENTAL
Intervention: beta-alanine supplementation
Number of subjects: 14
Study 32758017 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent A
Number of subjects: 0
Study 32758017 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent B
Number of subjects: 0
Study 33248595 — intervention group
Group type: EXPERIMENTAL
Intervention: Lohmann Brown-classic (LB) hens
Number of subjects: 20
Study 33248595 — intervention group
Group type: COMPARATOR
Intervention: Lohmann LSL-classic (LSL) hens
Number of subjects: 20